Abstract: The present invention concerns the use of Linomide, i.e. N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxa mide for the treatment of humans subjected to BMT, cytostatic treatment irradiations or combinations thereof.

Abstract: The present invention relates to a nicotine-impermeable container and a method for fabricating same. Additionally, the invention relates to a nicotine inhaling device which allows a user to ingest nicotine vapors orally. The nicotine inhaling device of the present invention is primarily directed to a device which can be used as a smoking cessation aid.

Abstract: An injection cartridge of the dual-chamber type has a bypass connection between its two chambers which is arranged such that the interior wall of the cartridge is modified in a determined area in such a way that the movable wall between the two chambers does not seal completely against the interior wall in said area.

Abstract: A carrier composition that is a liquid at or below room temperature forms a high viscosity layer or gel at body temperature, which comprises a water-soluble, nonionic cellulose ether having a cloud point not higher than 40.degree. C., a charged surfactant and optional additives in water. The carrier composition can be used for oral or local administration of a pharmacologically active substance to the skin, mucous membrane, the eye or a body cavity.

Abstract: The present invention relates to the use of iGF-II or effective analogues thereof for the manufacture of a medicament for prevention or treatment of nutritional or gastrointestinal disorders and for promoting human or animal neonatal growth. It also relates to composition comprising exogenous human or animal IGF-II or effective analogues thereof in a therapeutically effective amount together with a pharmaceutically acceptable carrier or diluent or foodstuff, preferably in admixture with artificial or natural milk or colostrum. The invention may be applied both in man and in animals.

Abstract: A melt granulating method for the production of pellets (spheres) which contain a therapeutically active substance of high-dosage type. The method is characterized by: (i) mechanically working a mixture which contains (a) the active substance in cohesive form and (b) a binder (melting point 40.degree. C.-100.degree. C.) while supplying sufficient energy for the binder to melt and to form spherical overwetted pellets; (ii) adding further cohesive substance, while maintaining the mechanical working; (iii) interrupting the mechanical working and supply of energy and cohesive substance when the desired mean particle size of dry pellets (spheres) has been achieved; and (iv) removing the smallest and largest particles and dividing the remaining pellets into dosage batches. A novel pharmaceutical composition containing a dosage of 300-500 mg of pellets is obtainable from this process.

Abstract: The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.

Abstract: The invention relates to a novel process for the preparation of 13,14-dihydro-15 (R)-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. isopropyl ester of the formula (I)--wherein R stands for saturated or unsaturated straight, branched or cyclic C.sub.

Abstract: A dietary fibre composition comprising a water-soluble, nononic cellulose ether having a cloud point not higher than 35.degree. C. in combination with a charged surfactant and optional additives in water, the ratio of surfactant to cellulose ether being 1:5 to 1:25 by weight, is a liquid solution at room temperature and a gel in the gastrointestinal tract at body temperature. The dietary fibre composition can be used as a bulk laxative and also as a slimming aid.

Abstract: Disclosed are emulsions for intravenous administration based on lipophilic iodized and/or bromated substances with emulsifiers and containing derivatives of cyclopenta-phenanthrene, wherein the weight ratio between emulsifier and derivative in the emulsion is between 10:1 and 1:2. These emulsions are intended for use as X-ray contrast agent, particularly for visibilizing the presence of tumors, metastases and the like in liver and spleen. The derivative of cyclopenta-phenanthrene is preferably cholesterol, phytosterol, sitosterol, sigmasterol and/or campesterol. The invention also relates to a method for preparing the emulsion and to the use of the emulsion in the preparation of an X-ray contrast medium for computed tomographic examinations.

Abstract: The invention relates to an emulsion which comprises phospholipids containing omega-3-fatty acids such as DHA and EPA in a high amount and a vegetable oil and/or marine oil. It also relates to the use of phospholipids containing the omega-3-fatty acids such as DHA and EPA in high amount for the manufacturing of a nutritive emulsion giving low serum triglyceride and cholesterol levels and for the manufacturing of a medicament with anti-inflammatory and immunosuppressive effects. The invention also discloses phospholipids containing omega-3-fatty acids such as DHA and EPA with therapeutic effects such as effects on inflammatory and immunologically active cells, e.g. rheumatoid arthritis and sepsis and an effect on normal brain and retina development and function and cardiovascular diseases. Also disclosed are pharmaceutical and nutritive compositions as well as lipid particles comprising the phospholipids.

Abstract: The present invention relates to the relief or prevention of withdrawal syndrome resulting from addiction to alcohol and/or the suppression of dependence on alcohol by administering to a person in need thereof, an effective amount certain diphenylbutyl-piperazine-carboxamides including 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethyl-1-piperazine-carboxamide which is also known as amperozide.

Abstract: In a method for producing intraocular lenses with improved optical properties, applying to the optical part of the lens a coating to protect the surface during one or more processing steps which are carried out under conditions so that the protective coating is essentially insoluble and remains adhered to the lens, and removing the coating by changing the conditions which make the coating adhere to the lens.

Abstract: This invention relates a method for topical treatment of glaucoma or ocular hypertension by administration of an effective intraocular pressure reducing amont of a prostaglandin derivative of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure. The invention further relates to compositions comprising said prostaglandin derivatives in an ophthalmologically compatible carrier.

Abstract: The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.

Abstract: A device for limiting the penetration of an injection needle when an injection is administered from an injection apparatus comprises an exterior sleeve (1) arranged around the front part of the injection apparatus (2). In its foremost position, the sleeve (1) surrounds the needle (8) completely, and it may be displaced rearwards while overcoming a spring force (6), to expose the needle (8).

Abstract: A compound of the formula Het--NR--SO.sub.2 --Ph.sup.2 --A--Ph.sup.1 (COOH)(OH) and tautomic form, salts, solvates, C.sub.1-6 alkyl esters and pharmaceutical compositions of the compound. Ph.sup.1 and Ph.sup.2 are benzene rings with the proviso that carboxy and hydroxy are ortho to one another. Het includes an optionally substituted heterocyclic ring which includes conjugated double bonds and binds to nitrogen in NR. The compound is characterized in that A is a bridge which is stable against reduction because it is not azo, and in that R is hydrogen or lower alkyl.The invention also includes the preparation of the compound and its use as a drug, particularly for treating autoimmune diseases.

Abstract: Device and method for dosing a liquid product from a tubular container are provided. The container includes a plurality of doses of the liquid product and a plate for pinching the container together locally such that it is divided into a plurality of separate liquid chambers containing a desired dose.

Abstract: Method for extracapsular cataract extraction with or without posterior chamber intraocular lens implantation comprising chemical modification of the posterior surface of the lens capsule, at least in the optical portion of said capsule, for preventing cell attachment and growth.

Abstract: An intraocular lens that includes an optical lens body and haptics extending outwardly from the optical lens, said haptics extending at about a zero degree of angulation with respect to the lens body when not under compression and at least one haptic having at least one segment which is formed so that upon compression of the haptics under conditions similar to implantation said at least one segment will create a torque which causes the lens to vault in only one predetermined direction and to a predetermined angulation greater than zero.